|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||3.3800 - 3.7100|
|52 Week Range||1.0400 - 5.4000|
|Beta (5Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 06, 2017 - Dec 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.38|
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that Sandra Aung, Ph.D. joined the Company as Senior Vice President, Chief Clinical Development Officer.
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral cancer immunotherapies, today announced the issuance of a new patent covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO™. Specifically, on October 6, 2020, the United States Patent and Trademark Office issued U.S. Patent No. 10,792,375, entitled Method for the Treatment of Malignancies, which covers the Company's interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO™, and its proprietary EP gene delivery system. This patent covers the use of intratumoral electroporation of DNA encoding interleukins (such as IL-12) to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and the University of South Florida Morsani College of Medicine to evaluate its lead product candidate, TAVO™ (interleukin-12 or IL-12 plasmid) immunotherapy as neoadjuvant treatment (administered before surgery) in combination with intravenous OPDIVO® (nivolumab) in up to 33 patients with operable locally/regionally advanced melanoma.